Sign in

Trial result ·

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This was an early-stage trial of a new nanoparticle drug, called PPM. It was for bladder cancer that had not responded to BCG treatment. The nanoparticle is designed to carry paclitaxel to cancer cells. It is given into the bladder once weekly for 6 weeks. Doses are 25 mg, 50 mg or 75 mg. Up to 29 people will be enrolled. The main goals are safety and the dose for later trials.

What they found

These are preliminary results. The first patients completed their course at the starting dose level. No drug-related adverse events were seen. Complete remission was seen in some of these first patients. The study is still open for enrollment.

What it means for patients

The authors say this first-in-human trial aims to test safety and toxicity. It also aims to set the dose for later study. Final conclusions are not given in the abstract.

Why it is not certain yet

Only the first patients are reported so far. The trial has no comparison group. The study is still open. The abstract does not give final results.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

PubMed · PMID 42415671

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Bladder cancer publications